Emerging Markets

October 2013

Acute Coronary Syndrome in Russia

Report Authors
Laurie DiModica, M.S.
Natalia Reoutova, M.A., M.Sc.
Donal Minihan, M.V.B., Ph.D.
  • Pages:117
  • Tables:29
  • Figures:79
  • Citations:0
  • Drugs:54
  • Interviews:8

Introduction:

In Russia, as in Western markets, polypharmacy plays a critical role in the management of patients with acute coronary syndrome (ACS), a factor which has led to development of a broad treatment armamentarium of multinational corporation (MNC) brand and generic drugs in this country. Through the 2012-2017 period, additional entries will expand the Russian ACS market both in total patient share percentage and sales. However, factors such as drug price controls and an average monthly income that limits patients’ accessibility to drugs paid out-of-pocket will temper ACS market growth potential.

Questions Answered in This Report:

  *   The Russian ACS market will grow 5.4% annually between 2012 and 2017 with the launch and uptake of novel therapies. What was the size of the Russian ACS market in 2012? How large will the market be in 2017? How will novel therapies emerging for ACS in the next five years change the Russian market? What factors will drive growth in this market? What are the opportunities for ACS drug manufacturers and developers?

  *   Russian cardiologists express a preference for MNC brands for treating their patients with ACS, and the efficacy of MNC brands is paramount to drug selection. What other factors drive Russian physicians’ prescribing habits in relation to ACS therapeutics? How will generic erosion affect MNC brands in Russia, and what impact will generic erosion have on prescribing patterns? Which brand will be the top-selling product in 2017?

  *   Russia has a high rate of full or partial government payment for many ACS therapies, yet patients are expected to shoulder more of the cost of certain agents. Which agents enjoy full or partial government coverage, and which do patients largely access through private insurance or out-of-pocket expenditure? For which therapies might cost limit uptake given government coverage rates and patients’ income levels? How do brand prices in Russia compare with the brand prices in other countries?

Scope:

Primary research: 90 cardiologist surveys across Russia. Separate in-depth interviews with 8 cardiologists.

Epidemiology: Diagnosed ACS events: total; by age-group; by ACS subtype. Drug-treated ACS events. Drug-treated incident ACS cases that have survived 12 months. Ten-year epidemiology forecasts through 2022.

Market forecast features: Our analysis evaluates the size of the population with access to medical care, rates of diagnosis of ACS, and rates of drug treatment. We include a detailed forecast for ACS drug classes and leading products for the 2012-2017 period using an epidemiology-based, bottom-up market model.


Search Reports

Mentioned in this report:

  • - Abbott
  • - Amgen
  • - AstraZeneca
  • - Bayer
  • - Boehringer Ingelheim
  • - CSL Behring
  • - Daiichi Sankyo
  • - Eli Lilly
  • - Evapharm
  • - GlaxoSmithKline
  • - Janssen
  • - Johnson & Johnson
  • - Merck
  • - Merck KGaA
  • - Novartis
  • - Pfizer
  • - Regeneron
  • - Roche
  • - Sanofi
  • - The Medicines Company
Decision Resources Group brands include: